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Abstract  
Introduction: Worldwide, Non-alcoholic fatty liver disease (NAFLD) has become an important cause of chronic liver disease and cardiovascular 
morbidity, even more so in subjects with Type II Diabetes Mellitus (T2DM). The aim of this study was to determine the prevalence and risk factors 
of NAFLD in an African population with Type II Diabetes Mellitus. Methods: We performed a case control study and evaluated anthropometric and 
biochemical risk factors for NAFLD in 336 subjects (T2DM and non-diabetic controls). Parameters assessed included estimation of BMI (Body Mass 
Index), measurement of waist circumference (WC), serum cholesterol including HDL-C, LDL-C and triglyceride and serum transaminases (ALT and 
AST). Hepatitis B and C viral antibody screening was also performed. The diagnosis of NAFLD was confirmed by identification of hepatic steatosis 
on abdominal ultrasound scan evaluation and exclusion of significant alcohol consumption. Results: NAFLD was identified in 16.7% (28 of 168) 
patients with T2DM compared with 1.2% (2 of 168) non-diabetic controls (Odds Ratio 16.6; p<0.001). Central obesity (WC > 102cm) and 
dyslipidaemia (HDL-c < 40mg/dl) were independently associated with NAFLD in male subjects with T2DM (p=0.03 and p=0.04 respectively). 
Conclusion: NAFLD occurred more frequently in patients with T2DM than controls and was associated with central obesity and dyslipidaemia. The 
diabetic subjects with NAFLD will require more intensive therapy to decrease the risk of hepatic, cardiovascular and other adverse events. 
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Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of clinical 
and pathological conditions characterized by excessive lipid 
deposition in the liver parenchyma in the absence of significant 
alcohol consumption [1].In the past decade, NAFLD has gained 
worldwide prominence as an important public health condition 
because of the enhanced risk of progressive end-stage liver disease, 
liver failure and hepatocellular carcinoma [2,3].Current evidence 
suggests that NAFLD is the hepatic component of the metabolic 
syndrome, a syndrome that also includes central obesity, 
dyslipidemia, hypertension and insulin resistance/impaired glucose 
tolerance [3-5]. Recently published cross-sectional and prospective 
cohort studies suggest that 19% to 30% of asymptomatic adults in 
the USA and Europe have NAFLD [6,7].The prevalence of NAFLD 
among people with Type II Diabetes Mellitus (T2DM) is significantly 
higher than reported in the general population and ranges from 
21%-78% [4,8-10]. In T2DM, NAFLD pursues a more aggressive 
clinical course with necro-inflammation and fibrosis and progression 
to end-stage chronic liver disease. Beyond these hepatic 
consequences, NAFLD is being increasingly associated with an 
excess risk of cardiovascular disease, coronary artery disease, as 
well as peripheral vascular disease [11-13]. In African populations, 
there is a dearth of evidence on the prevalence and characteristics 
of NAFLD. Kruger et al [14], histologically confirmed NAFLD in 45% 
of an obese population in Western Cape, South Africa. They 
convincingly demonstrated a strong association between obesity, 
NAFLD and insulin resistance. This study was the first to describe 
the clinical characteristics of NAFLD in South Africa, using a study 
population comprised mostly of Caucasian subjects with only a 
minority of Africans. There however remains a dearth of 
epidemiological and clinical evidence on NAFLD in black Africans. 
The aim of this study was to determine the prevalence and risk 
factors for NAFLD in black Africans with T2DM. The findings from 
this study will provide an opportunity to enhance awareness of this 
condition and contribute to the evaluation and clinical management 





The study was conducted at a University Teaching hospital in Lagos, 
South-West, Nigeria. The hospital is a 760-bed federal tertiary 
referral centre providing both medical and surgical care to the 
general population of Lagos. Consecutively presenting adults >18 
years old with diabetes were evaluated at the endocrine clinic 
between November 2011 and January 2012. Included were patients 
with established T2DM diagnosed according to the American 
Diabetes Association (ADA) diagnostic criteria [16] (ie symptoms of 
diabetes plus random plasma glucose concentration ≥ 200 mg/dl or 
fasting Plasma Glucose (FPG) ≥ 126 mg/dl). Controls were age and 
sex matched, non- diabetic patients with no history suggestive of 
diabetes eg polyuria, polydipsia, unintentional weight loss and 
fasting blood sugar level less than 126 mg/dl. Exclusion criteria 
included alcohol intake in excess of 20 grams per day, history of 
jejunoileal bypass surgery or extensive small bowel resection, usage 
of drugs known to cause secondary steatosis like corticosteroids, 
methotrexate, and amiodarone. Pregnant women and subjects with 
severe co- morbidities such as malignancies, congestive heart failure 
and chronic kidney disease were excluded. A structured 
questionnaire was administered to each subject to obtain 
information such as bio-data, alcohol intake, current medications as 
well as family history of diabetes and liver disease. All patients were 
clinically evaluated and weight (kg) and height (m) were measured. 
The Body Mass Index (BMI=weight (kg) /height (m2) was 
calculated and classified based on World Health Organisation (WHO) 
criteria [17]. Waist circumference was measured from the right side 
in the mid-axillary line, midway between the lower margin of the 
least palpable rib and the top of the iliac crest (highest point of the 
hip bone on the right side) as the point of reference. Hip 
circumference measurement (HC) in centimetres was done at the 
point of widest circumference of the buttocks with the tape parallel 
to the floor. Both waist and hip circumference was taken twice and 
the average was calculated [18].Central obesity was defined as 
waist circumference (WC) more than 88 cm in females and more 
than 102 cm in males. The average of three BP readings was 
calculated. Hypertension was considered at a blood pressure 
reading of more than or equal to 140/90 mmHg or current intake of 
anti hypertensive or both [19]. 
  
Blood samples were taken for evaluation of serum alanine 
transaminase (ALT), aspartate transaminase (AST), fasting lipid 
profile including total cholesterol (TCHOL), high-density lipoprotein 
cholesterol (HDL-C), triglyceride (TG) (Randox Laboratory Limited, 
UK). Low-density lipoprotein cholesterol (LDL-C) was calculated 
using Friedwald formulae LDL= (TCHOL-HDL-C) -TG/5) [20]. 
Dyslipidemia was defined as having one or more of the criteria: 
LDL-C ≥100 mg/dL, total cholesterol ≥200 mg/dL, triglycerides 
≥150 mg/dL, or HDL-C < 40 mg/dL in males and <50 mg/dL in 
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females [19].Samples were also analysed for detection of anti-
hepatitis C virus and hepatitis B surface antigen (Diaspot, USA). 
Abdominal Ultrasound scan (USS) evaluation was performed (Aloka 
Pro-sound 3500, Japan) using a 3.75 MHz probe. Findings 
suggestive of hepatic steatosis included "bright liver" with increased 
echogenicity, hepato-renal contrast and attenuation of the 
diaphragm [20,21]. The diagnosis of NAFLD was based on the 
absence of alcohol consumption (or alcohol intake less than 20 
grams per day) and the presence of hepatic steatosis on USS 
evaluation. Ethical approval was obtained from the Ethics and 
Research committee of Lagos University Teaching Hospital Idi- 
Araba, Lagos, Nigeria prior to commencement of the study. Pre 
study counselling was done and written informed consent was 
obtained from all patients prior to enrolment. Minimal sample size 
was determined using the Cochrane statistical formula [22].Total 
study population was estimated to be 320 subjects. Data analysis 
was performed using SPSS Version 20 (SPSS Inc, Chicago, IL USA). 
Cases and controls were compared using Chi-square or Fisher's 
exact test to assess significance between proportions and Students 
t-test to assess significance with quantitative data. Variables 
associated with NAFLD, with a significant P-value < 0.05 in 
univariate analysis, were included in a multivariable logistic 
regression. Relationships were assesses by Odds ratio (OR) and 





Characteristics of study subjects 
  
A total of 340 subjects were recruited of which 336 subjects (168 
subjects with T2DM and 168 control subjects without T2DM) were 
included in data analysis. 4 subjects were excluded due to 
incomplete laboratory evaluation. The mean age (standard 
deviation) of the patients with T2DM was 53.2 (8.6) years. There 
were 109 (64.9%) female and 59 (35.1%) males, with a Male to 
Female ratio of 1: 1.8. Most of the T2DM subjects (60%, n=101) 
had only basic education and 88% (n=148) earned an income of 
less than three hundred US dollars ($300)/month). There was no 
significant difference between the cases and control subjects in 
terms of age, gender, educational background and monthly income. 
The T2DM subjects were however significantly more likely to have 
concurrent hypertension (n=80, 47.6%) and a family history of 
diabetes (n=74, 44%) compared to the non-diabetic controls (Odds 
Ratio 3.2, p<0.001 and Odds ratio 6.5, p<0.001 respectively). The 
socio demographic variables of the study population are shown 
in Table 1. 
  
Anthropometric, biochemical and ultrasound characteristics 
of study participants 
  
As shown in Table 2, subjects with T2DM were significantly more 
likely to be overweight and have higher waist/hip ratio than the 
controls (p=0.02 and p<0.001 respectively). The mean systolic 
blood pressure was significantly higher among the cases compared 
with the controls (p<0.001). T2DM subjects had a higher prevalence 
of dyslipidaeamia with mean total serum cholesterol and LDL-
cholesterol significantly higher compared to the control subjects 
(p<0.001 and p<0.001 respectively). Although the mean AST and 
ALT values appeared higher in diabetics than controls, this 
association failed to reach statistical significance (p=0.05 and 
p=0.17 respectively). The distribution of clinical and laboratory 
characteristics of the study participants is shown in Table 2. 
Antibodies to Hepatitis C virus (anti HCV) were negative in all the 
study participants. Seven (7) subjects however were positive for 
Hepatitis B virus. Hepatic steatosis was detected on ultrasound scan 
evaluation in 28 of 168 (16.7%) T2DM subjects compared to 2 of 
168 (1.2%) control subjects. (Odds Ratio 16.6, p<0.001).These 
subjects did not have a history of alcohol use (or consumed less 
than 20 grams of alcohol per day) and thus fulfilled the criteria for 
NAFLD. 
  
Characteristics of NAFLD among subjects with T2DM 
  
The characteristics of NAFLD in the diabetic subjects are shown 
in Table 3. NAFLD occurred more frequently in men (n=12/59, 
20.3%) than in women (n=16/109, 14.7%). Subjects with NAFLD 
also appeared to have higher levels of ALT, AST and fasting serum 
triglyceride than subjects without NAFLD. These differences 
however did not attain statistical significance (p=0.53, p=0.4 and 
p=0.06 respectively). A high frequency of obesity (BMI ≥ 30 kg/m2) 
and central obesity (WC >88 cm) was noted in women with T2DM 
regardless of NAFLD status (p=0.19 and p=0.35 respectively). In 
contrast, diabetic men with NAFLD had a significantly higher 
prevalence of generalized obesity (BMI ≥ 30 kg/m2) than those 
without NAFLD (58.3% vs. 25.5%; Odds Ratio 4.0; 95% CI; 1.1-
15.3). These men also had an 8-fold risk of central obesity with WC 
>102 cm (9 of 12 subjects, 75%) and a higher prevalence of 
dyslipidaemia (HDL-c <40 mg/dl in 4 of 12 subjects, 33.3%) than 
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T2DM men without NAFLD (p=0.002 and p=0.013 respectively) as 





In this study, we have shown that up to 16.7% (one in six) of the 
subjects with T2DM had NAFLD, a 16-fold risk of NAFLD compared 
to non-diabetic controls. Our finding of NAFLD in both the subjects 
with T2DM and non-diabetic controls corroborates a prior survey 
from West Africa that reports a prevalence of NAFLD in 9.5% of 
diabetics and 4.5% of non-diabetic controls [23]. There is however 
a paucity of evidence in this region. A significantly higher prevalence 
of NAFLD ranging from 40% to 60% of subjects with T2DM has 
been reported in Caucasian [11], Indian [24,25] and Asian 
populations [26]. In the USA, the prevalence of NAFLD in the 
general population varies from 15% in Caucasians to 28% in 
Hispanics [6].The comparatively lower prevalence of NAFLD in our 
study may be a reflection of the different socio-demographic and 
economic characteristic of this African population. The association of 
obesity and increasing BMI is an established risk factor for NAFLD 
worldwide. In this current study, the mean body mass index (BMI) 
and income characteristics suggest that this population is not 
significantly obese and appear less affluent than western 
populations. This is not surprising as subjects were recruited from a 
large urban public hospital in a resource-limited setting. In addition, 
diagnostic tools used for evaluation of hepatic steatosis have 
differing accuracy in estimating hepatic fat. The computerized 
tomography (CT) scan and magnetic resonance imaging (MRI), 
although more sensitive in detecting minimal levels of hepatic 
steatosis, are expensive and impractical as screening tools [20,21]. 
The ultrasound scan (USS) has greater than 90% sensitivity and 
specificity in diagnosing hepatic steatosis and was used in this 
study. It remains the screening modality of choice because of low 
cost, safety, and accessibility [21]. Another important reason for the 
differing distribution of NAFLD appears to be related to the racial 
and ethnic characteristics of the population. In the US Multi-ethnic 
Study of Atherosclerosis (MESA), the prevalence of NAFLD in African 
Americans was found to be significantly lower than in Caucasian and 
Asian populations [6]. Various other studies corroborate this ethnic 
disparity [27-29]. Recent evidence from prospective multi-ethnic 
cohort studies have identified a strong association between NAFLD 
and genetic mutation in several genes including lipolytic enzymes, 
patatin like phospholipase (PNPLA-3) domain, neurocan gene NCAN 
and glucokinase regulatory protein gene GCKR in non-Hispanic 
whites and subjects of European descents respectively 
[28,29].These findings suggest a racial susceptibility to NAFLD and 
may have implications for African and other populations and require 
further research. 
  
Risk factors for NAFLD 
  
The association of obesity, concurrent hypertension and 
dyslipidaemia is not surprising and has been well characterized in 
diabetic populations worldwide. The key pathogenesis of this 
association is related to insulin resistance and the metabolic 
syndrome [3,4]. Our study shows that central obesity and 
dyslipidaemia although significantly associated with T2DM, are also 
independent risk factors for NAFLD, more so in men than women. 
Diabetes and NAFLD have mutual pathogenetic mechanisms, which 
may interact with metabolic derangements to accelerate NAFLD 
progression in diabetic patients [10,11,25]. The male susceptibility 
to NAFLD as shown in this study has also been described in 
Caucasian and Hispanic populations and has been attributed to 
lifestyle, sex hormones, differing distribution of adiposity, and other 
behavioral and genetic factors that remain to be fully defined. 
Although our study identifies important characteristics and 
associations of NAFLD in this African population, there are a few 
limitations. The reliance on patient's estimate of their alcohol 
consumption is subject to recall and may be inaccurate. Additionally, 
the gold standard for diagnosis of fatty liver is the liver biopsy. This 






This study has shown that NAFLD is common in subjects with T2DM 
and is associated with a 16-fold risk compared to non-diabetic 
controls. Although obesity, hypertension and dyslipidaemia were 
also significantly associated with T2DM, our study suggests that 
central obesity and dyslipidaemiaare also independent risk factors 
for NAFLD, more so in men than women. Our result supports a role 
for routine ultrasound scan evaluation in T2DM to enhance clinical 
decision making and enable early recognition and management of 
NAFLD to limit its associated adverse hepatic and cardiovascular 
complications. 
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What is known about this topic 
 The association of obesity, concurrent hypertension and 
dyslipidaemia has been well characterized in diabetic 
populations worldwide; 
 In Western countries, patients with diabetes are a high 
risk group for NAFLD; 
 They have a more aggressive clinical course with necro-
inflammation and progression to liver disease and 
enhanced cardiovascular risk. 
 
What this study adds 
 In Nigerians, T2DM is associated with a 16- fold risk of 
NAFLD compared to non-diabetic controls; 
 Nigerian men with T2DM appear more susceptible to 
NAFLD than women and have a significant association of 
NAFLD with truncal obesity and dyslipideamia; 
 Prevalence of NAFLD in this population is lower than in 
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AGE mean, years (SD) 53.17±8.6 52.01±8.9 0.1 
Gender       
0.11 Females 109 (64.9) 97 (57.7) 
Males 59 (35.1) 71 (42.3) 
Level of Education       
  
0.08 
None 4 (2.4) 3 (1.8) 
Primary 43 (25.6) 28 (16.7) 
Secondary 58 (34.5) 73 (43.5) 









0.10 <300 148(88.1) 149 (88.7) 
>300 20 (11.9) 19 (11.3) 
Concurrent     
<0.001a 
Hypertension 80 (47.6) 37(22.0) 
Family history of DM 74(44.0) 18(10.7) <0.001b 
*Inclusive of University, Polytechnic, Teacher training college 
a- Odds Ratio 3.2, 95% Confidence Interval  2.00-5.17, 


























































BMI (kg/ m2) 28.47±4.39 27.42±5.09 0.02 
Waist Hip Ratio;   
  
Females 0.93±0.07 0.89±0.07 0.00 
Males 0.94±0.06 0.89±0.07 0.00 
Systolic BP (mmHg) 130.41±18.99 123.05±17.74 0.00 
Diastolic BP (mmHg) 80.59±12.87 79.92±11.54 0.30 
AST (IU/L) 6.49±3.41 5.86± 3.70 0.05 
ALT (IU/L) 9.07± 4.34 8.43±7.59 0.17 
TCHOL (mg/dl) 179.49±40.89 170 ±31.69. 0.00 
LDL-C (mg/dl) 94.46±40.57 81.26±32.94 0.00 
HDL-C (mg/dl) 71.07 ±25.25 73.89±23.32 0.14 
Triglyceride (mg/dl) 75.22±37.96 80.07±31.47 0.10 
Hepatic steatosis 
Identified on USS (n,%) 
28 (16.7%) 2 (1.2%) 0.00* 
SD standard deviation, AST, aspartate aminotransferase, ALT alanine aminotransferase, TCHOL total cholesterol, LDL-C 
Low density lipoprotein, HDL-C high density cholesterol, USS ultrasound scan. *Odds Ratio, 16.6; 95% CI (3.9-70.9) 
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 Table 3: Univariate analysis of the clinical and biochemical factors associated with NAFLD among subjects with T2DM  
Variables        








Mean Age, yrs ±SD 53.17 ± 8.6 53.1±8.3 53.2±8.7 0.98 
Gender   
    
0.4 
Male: 59 (35.1) 12 (20.3) 47 (79.6) 
Female 109 (64.9) 16 (14.7) 93 (85) 
BMI female (≥30 kg/m2) 42 (38.5) 9 (56.3) 33 (35.5) 0.19 
BMI Male (≥30 kg/m2) 19 (32.2) 7 (58.3) 12 (25.5) 0.04* 
WC Males > 102cm 21 (35.6) 9(75) 12 (25.5) 0.002** 
WC Females >88cm 84 (77.1) 14 (87.5) 70 (75.3) 0.35 
AST  >12 IU/L 8 (4.8) 2(7.1) 6(4.3) 0.40 
ALT  > 12 IU/L 16 (9.5) 3(10.7) 13(9.3) 0.53 
T-CHOL ≥ 200 mg/dl 46 (27.4) 5(17.9) 41(29.3) 0.16 
HDL-c         
Female <50 mg/dl 30 (28.3) 5 (31.3) 25 (26.9) 0.76 
Male <40 mg/dl 6 (10.2) 4 (33.3) 2 (4.3) 0.013 
LDL-c ≥ 100 mg/dl 76 (45.2) 15(53.6) 61(43.6) 0.22 
Triglyceride  >150mg/dl 10 (5.9) 4 (14.3) 6 (4.3) 0.06 
WC waist circumference, BMI Body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, T-CHOL total 
cholesterol, LDL-c Low density lipoprotein, HDL-c high density lipoprotein-cholesterol. NAFLD non-alcoholic fatty liver disease. 
* Odds ratio 4; 95% CI; 1.1-15.3,  ** Odds ratio 8.7; 95% CI:2.1-37 
